Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Mahamaya Lifesciences Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹180.70 |
|---|---|
| Day's Range | ₹180.25 - ₹182.45 |
| Open | ₹182.45 |
| 52 Week Range | ₹111.00 - ₹205.05 |
| Volume | 13,200 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 23.89 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 25.60 |
| TTM EPS (₹) | 7.06 |
| P/E Ratio | 21.32 |
| Book Value(₹) | 3.47 |
| PAT Margin (%) | 5.02 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 20.27 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 2657.51 |
| Expenses | N/A | N/A |
| PBT | N/A | 172.52 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 128.12 |
About Mahamaya Lifesciences Ltd.
| Founded | 2016 |
|---|---|
| Managing Director | Krishnamurthy Ganesan |
Latest News
Sep
30
2026
Posted on Sep 30th 2026
Mahamaya Lifesciences informs about change in management
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of the said Regulations, Mahamaya Lifesciences has informed that the members of the Company, based on the recommendations of Board of Directors & Nomination and Remuneration Committee approved the following resolutions at their meeting held on Tuesday, September 29, 2026, at 11:00 AM: Appointment of Dr. Bhagirath Choudhary as Independent Director, Re-appointment of Dr. Charudatta Digambar Mayee as Independent Director, Re-appointment of Gopal Krishna Raju as Independent Director, Re-designation of Krishnamurthy Ganesan as Chairman, and Re-designation of Prashant Krishnamurthy as Managing Director.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
20
2026
Posted on Oct 20th 2026
Aksharchem (India) - Quaterly Results
The topline advanced to Rs. 1604.82 millions, up 79.71% for the September 2026 quarter as against Rs. 893.02 millions during the year-ago period.The Total Profit for the quarter ended September 2026 of Rs. 133.21 millions grew from Rs.-13.70 millionsOperating profit for the quarter ended September 2026 rose to 210.09 millions as compared to 23.86 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 1604.82 | 893.02 | 79.71 | 3013.52 | 1862.64 | 61.79 | 3724.30 | 3462.65 | 7.56 |
| Other Income | 0.34 | 0.34 | 0.00 | 0.68 | 0.70 | -2.86 | 1.98 | 2.55 | -22.35 |
| PBIDT | 210.09 | 23.86 | 780.51 | 436.61 | 88.36 | 394.13 | 172.06 | 250.88 | -31.42 |
| Interest | 24.71 | 13.81 | 78.93 | 48.03 | 28.10 | 70.93 | 68.16 | 52.60 | 29.58 |
| PBDT | 185.38 | 27.01 | 586.34 | 388.58 | 77.22 | 403.21 | 120.86 | 198.28 | -39.05 |
| Depreciation | 44.53 | 41.07 | 8.42 | 88.25 | 80.96 | 9.00 | 165.28 | 140.02 | 18.04 |
| PBT | 140.85 | -14.06 | -1101.78 | 300.33 | -3.74 | -8130.21 | -44.42 | 58.26 | -176.24 |
| TAX | 7.64 | -0.36 | -2222.22 | 15.00 | 2.85 | 426.32 | -40.04 | 10.56 | -479.17 |
| Deferred Tax | 7.64 | -0.36 | -2222.22 | 15.00 | 2.85 | 426.32 | -40.04 | 10.56 | -479.17 |
| PAT | 133.21 | -13.70 | -1072.34 | 285.33 | -6.59 | -4429.74 | -4.38 | 47.70 | -109.18 |
| Equity | 80.33 | 80.33 | 0.00 | 80.33 | 80.33 | 0.00 | 80.33 | 80.33 | 0.00 |
| PBIDTM(%) | 13.09 | 2.67 | 389.98 | 14.49 | 4.74 | 205.42 | 4.62 | 7.25 | -36.24 |
Read More
Oct
20
2026
Posted on Oct 20th 2026
Bhansali Engg. Poly. - Quaterly Results
The September 2026 quarter revenue stood at Rs. 4033.70 millions, up 24.08% as compared to Rs. 3250.98 millions during the corresponding quarter last year.The Profit for the quarter ended September 2026 of Rs. 630.32 millions grew by 57.25% from Rs. 400.85 millions.The company reported a good operating profit of 895.05 millions compared to 567.45 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 4033.70 | 3250.98 | 24.08 | 8755.23 | 6330.07 | 38.31 | 12760.04 | 13977.44 | -8.71 |
| Other Income | 106.12 | 76.63 | 38.48 | 203.66 | 201.51 | 1.07 | 401.06 | 382.91 | 4.74 |
| PBIDT | 895.05 | 567.45 | 57.73 | 1818.47 | 1217.84 | 49.32 | 2563.38 | 2527.86 | 1.41 |
| Interest | 0.39 | 0.60 | -35.00 | 1.28 | 1.04 | 23.08 | 2.06 | 1.94 | 6.19 |
| PBDT | 894.66 | 566.85 | 57.83 | 1817.19 | 1216.80 | 49.34 | 2561.32 | 2525.92 | 1.40 |
| Depreciation | 20.38 | 21.16 | -3.69 | 40.75 | 43.12 | -5.50 | 83.65 | 90.02 | -7.08 |
| PBT | 874.28 | 545.69 | 60.22 | 1776.44 | 1173.68 | 51.36 | 2477.67 | 2435.90 | 1.71 |
| TAX | 243.96 | 144.84 | 68.43 | 494.73 | 305.52 | 61.93 | 673.00 | 637.71 | 5.53 |
| Deferred Tax | 2.80 | -1.42 | -297.18 | 3.55 | 1.08 | 228.70 | -0.19 | 1.48 | -112.84 |
| PAT | 630.32 | 400.85 | 57.25 | 1281.71 | 868.16 | 47.64 | 1804.67 | 1798.19 | 0.36 |
| Equity | 248.86 | 248.86 | 0.00 | 248.86 | 248.86 | 0.00 | 248.86 | 248.86 | 0.00 |
| PBIDTM(%) | 22.19 | 17.45 | 27.13 | 20.77 | 19.24 | 7.96 | 20.09 | 18.09 | 11.08 |
Read More
Oct
20
2026
Posted on Oct 20th 2026
Tatva Chintan Pharma - Quaterly Results
The topline surged 79.08% to Rs. 2074.84 millions for the September 2026 quarter as against Rs. 1158.63 millions during the corresponding quarter last year.Profit for the quarter ended September 2026 rises by 72.09% to Rs. 153.87 millions from Rs. 89.41 millions.OP of the company witnessed a marginal growth to 339.38 millions from 219.03 millions in the same quarter last year.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 2074.84 | 1158.63 | 79.08 | 3541.86 | 2250.43 | 57.39 | 4962.96 | 3664.15 | 35.45 |
| Other Income | 27.05 | 7.94 | 240.68 | 67.38 | 21.63 | 211.51 | 35.28 | 35.61 | -0.93 |
| PBIDT | 339.38 | 219.03 | 54.95 | 619.96 | 383.39 | 61.70 | 928.58 | 294.05 | 215.79 |
| Interest | 27.09 | 5.07 | 434.32 | 47.90 | 9.20 | 420.65 | 28.51 | 12.90 | 121.01 |
| PBDT | 312.29 | 213.96 | 45.96 | 558.88 | 374.19 | 49.36 | 900.07 | 281.15 | 220.14 |
| Depreciation | 107.92 | 90.53 | 19.21 | 213.57 | 180.22 | 18.51 | 368.42 | 276.54 | 33.22 |
| PBT | 204.37 | 123.43 | 65.58 | 345.31 | 193.97 | 78.02 | 531.65 | 4.61 | 11432.54 |
| TAX | 50.50 | 34.02 | 48.44 | 86.98 | 53.23 | 63.40 | 140.83 | 1.34 | 10409.70 |
| Deferred Tax | 32.81 | 12.59 | 160.60 | 69.29 | 19.68 | 252.08 | 40.16 | 1.32 | 2942.42 |
| PAT | 153.87 | 89.41 | 72.09 | 258.33 | 140.74 | 83.55 | 390.82 | 3.27 | 11851.68 |
| Equity | 233.92 | 233.92 | 0.00 | 233.92 | 233.92 | 0.00 | 233.92 | 233.92 | 0.00 |
| PBIDTM(%) | 16.36 | 18.90 | -13.47 | 17.50 | 17.04 | 2.74 | 18.71 | 8.03 | 133.15 |
Read More
Oct
19
2026
Posted on Oct 19th 2026
Punjab Chemicals & Crop Protection informs about board meeting
Punjab Chemicals & Crop Protection has informed that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 to consider and approve the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended 30th September 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Mahamaya Lifesciences Ltd. is ₹180.70 as of 2026-10-19.
The market capitalisation of Mahamaya Lifesciences Ltd. is ₹422.93 as of 2026-10-19.
The 1-year return of Mahamaya Lifesciences Ltd. is % as of .
The P/E ratio of Mahamaya Lifesciences Ltd. is 21.32 as of 2026-10-20.
The 52-week high and low of Mahamaya Lifesciences Ltd. are ₹205.05 and ₹111.00, respectively, as of 2026-10-19.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
